title: [Outcome of children and adolescents with Burkitt lymphoma and diffuse large B cell lymphoma treated with a modified NHL-BFM-90 protocol].
abstract: OBJECTIVE
  To evaluate the efficacy of a modified NHL-BFM-90 protocol in childhood and adolescence with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  A total of 138 de novo patients with BL and DLBCL were enrolled. All patients were stratified into low (R1), intermediate (R2) and high risk (R3) groups based on the stage, chemotherapy response and LDH level, and treated with a modified NHL-BFM 90 protocol.
  
  
  RESULTS
  Of the 138 patients, 105 were boys and 33 girls, with a median age at diagnosis of 7.5 yr (range 1.5 to 20.0 yr). Eighty-two cases were BL, 56 cases DLBCL. The patients with stage III/IV accounted for 76.1%. Thirty-one patients were assigned to group R1, 38 patients group R2, and 69 patients group R3. Complete remission (CR) after chemotherapy was 90.6%. At a median follow-up of 50 months(1-158 months), a total of 19 patients died of disease. The 5-year event free survival (EFS) and overall survival (OS) for the entire group were 85.8%, 85.8% respectively. 5-year EFS was 97.1% for stage I/II, 82.1% for stage III/IV respectively (P=0.039); and 96.7%, 86.8% and 80.2% for groups R1, R2 and R3 respectively (P=0.135); and 85.2% and 86.9% for BL and DLBCL respectively (P=0.635). Major toxicity was myelosuppression, which was tolerant and manageable.
  
  
  CONCLUSIONS
  That the modified NHL-BFM-90 protocol was highly effective for children and adolescents with BL and DLBCL, and especially improved the survival of the advanced patients.
authors.affiliation: Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China.
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Sun
authors.forename: Zi-jun
authors.initials: ZJ
authors.lastname: Zhen
authors.forename: Yi
authors.initials: Y
authors.lastname: Xia
authors.forename: Su-xia
authors.initials: SX
authors.lastname: Lin
authors.forename: Jia
authors.initials: J
authors.lastname: Zhu
authors.forename: Juan
authors.initials: J
authors.lastname: Wang
authors.forename: Su-ying
authors.initials: SY
authors.lastname: Lu
authors.forename: Fei-fei
authors.initials: FF
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Fei
authors.initials: F
authors.lastname: Zhang
authors.forename: Rui-qing
authors.initials: RQ
authors.lastname: Cai
authors.forename: Peng-fei
authors.initials: PF
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult